NCT01748383

This trial aims to investigate the use of stem cells from bone marrow during cardiac stenting for a first time ischaemic myocardial infarction. The trial is being conducted by the Russian Academy of Medical Sciences in Siberia and expects to enrol 85 subjects by September 2014. All participants will need to be diagnosed with a first-time ischaemic cardiac event-ST Elevation Myocardial Infarction (STEMI) and be scheduled for coronary artery stenting. Participants will be randomly divided into three groups. The control group will receive the coronary artery stenting only. The second group will have mesenchymal stem cells from their bone marrow infused at the time of stenting. The third group will have CD 133+ mononuclear cells isolated from their bone marrow infused at the time of stenting. All participants will be monitored for complications following the procedure, and changes in clinical condition including Left Ventricular Ejection Fraction.